Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 321,694,560
  • Shares Outstanding, K 2,533,028
  • Annual Sales, $ 60,115 M
  • Annual Income, $ 365,000 K
  • 60-Month Beta 0.38
  • Price/Sales 5.35
  • Price/Cash Flow 41.73
  • Price/Book 8.55
Trade MRK with:

Options Overview Details

View History
  • Implied Volatility 18.58% ( -2.66%)
  • Historical Volatility 18.62%
  • IV Percentile 25%
  • IV Rank 25.83%
  • IV High 26.55% on 10/20/23
  • IV Low 15.81% on 02/06/24
  • Put/Call Vol Ratio 0.64
  • Today's Volume 12,199
  • Volume Avg (30-Day) 21,177
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 370,400
  • Open Int (30-Day) 424,517

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 1.94
  • Number of Estimates 8
  • High Estimate 2.07
  • Low Estimate 1.80
  • Prior Year 1.40
  • Growth Rate Est. (year over year) +38.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
124.50 +4.39%
on 04/18/24
133.10 -2.36%
on 03/27/24
+4.65 (+3.71%)
since 03/25/24
3-Month
119.23 +9.00%
on 03/15/24
133.10 -2.36%
on 03/27/24
+9.83 (+8.18%)
since 01/25/24
52-Week
99.14 +31.09%
on 10/19/23
133.10 -2.36%
on 03/27/24
+13.43 (+11.52%)
since 04/25/23

Most Recent Stories

More News
Stocks Tumble on Tech Stock Weakness and Signs of Persistent Inflation

The S&P 500 Index ($SPX ) (SPY ) this morning is down -1.42%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.43%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.83%. US stock indexes...

$SPX : 5,002.53 (-1.36%)
SPY : 499.09 (-1.25%)
$DOWI : 37,764.89 (-1.81%)
DIA : 378.05 (-1.66%)
$IUXX : 17,249.74 (-1.58%)
QQQ : 420.13 (-1.50%)
ZNM24 : 107-095 (-0.41%)
META : 434.00 (-12.06%)
AMZN : 171.62 (-2.81%)
MSFT : 391.31 (-4.34%)
GOOGL : 154.96 (-2.62%)
TXT : 82.58 (-12.16%)
Merck: Q1 Earnings Snapshot

Merck: Q1 Earnings Snapshot

MRK : 129.15 (+1.69%)
MKKGY : 32.0700 (-1.14%)
Stocks Plunge Before the Open as Meta’s Revenue Forecast Disappoints, U.S. GDP Data and Earnings in Focus

June S&P 500 E-Mini futures (ESM24) are down -0.53%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.87% this morning as a disappointing revenue outlook for the current quarter from Meta weighed...

ESM24 : 5,030.25 (-1.51%)
NQM24 : 17,348.75 (-1.79%)
META : 434.00 (-12.06%)
TSLA : 166.66 (+2.79%)
HAS : 65.14 (+0.17%)
TXN : 174.07 (-0.42%)
ODFL : 194.24 (-0.42%)
MSFT : 391.31 (-4.34%)
GOOGL : 154.96 (-2.62%)
MRK : 129.15 (+1.69%)
GILD : 65.36 (-2.56%)
CAT : 338.84 (-6.79%)
Navigating the Surge in Aquaculture: Opportunities & Challenges

USA News Group – The way we get our food is in need of a dramatic overhaul, with domestic food inflation remaining high across the globe. However, one aspect of the world’s food supply that’s set...

BIOV.CN : 0.0850 (+6.25%)
BVAXF : 0.0623 (-0.32%)
MRK : 129.15 (+1.69%)
ZTS : 151.12 (+0.16%)
CTVA : 54.14 (-1.15%)
BG : 103.50 (-2.16%)
Option Volatility And Earnings Report For April 22 - 26

We’re all set for a massive week of earnings with with 52 companies of interest reporting. That’s the most in one week I can remember for a long time and is sure to have a big impact on where the market...

TSLA : 166.66 (+2.79%)
AMZN : 171.62 (-2.81%)
META : 434.00 (-12.06%)
MSFT : 391.31 (-4.34%)
GOOGL : 154.96 (-2.62%)
XOM : 120.19 (-0.71%)
V : 271.96 (-1.11%)
MRK : 129.15 (+1.69%)
BA : 160.31 (-2.45%)
DKNG : 40.29 (-1.37%)
ARM : 98.40 (-1.48%)
AMD : 152.69 (+0.63%)
New Home Sales Due Next Week in Canada

Monday U.S. Featured Earnings Verizon Communications Inc. (NYSE:VZ) (Q1) EPS of $1.12, ...

PSK.TO : 26.93 (-0.59%)
CDNS : 275.04 (-0.94%)
TFC : 37.93 (-2.22%)
TSLA : 166.66 (+2.79%)
V : 271.96 (-1.11%)
META : 434.00 (-12.06%)
TMO : 572.20 (-0.90%)
IBM : 167.45 (-9.04%)
ARE.TO : 17.30 (+3.53%)
MSFT : 391.31 (-4.34%)
AMZN : 171.62 (-2.81%)
MRK : 129.15 (+1.69%)
Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and

/CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab),...

MRK : 129.15 (+1.69%)
Better Growth Play: Merck or The Vanguard Growth Index Fund?

Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?

LLY : 723.80 (-1.15%)
PFE : 25.57 (-2.66%)
BMY : 45.17 (-7.55%)
NVO : 124.58 (-1.25%)
GILD : 65.36 (-2.56%)
MRK : 129.15 (+1.69%)
VUG : 325.14 (-1.79%)
Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.

Being able to stop a drug's unwanted effects could lead to a larger market share.

MRK : 129.15 (+1.69%)
1 New Green Flag for Moderna and Merck Stock

There's a new reason to believe that their joint projects are going well.

MRNA : 103.92 (-4.53%)
MRK : 129.15 (+1.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 130.18
2nd Resistance Point 128.89
1st Resistance Point 127.94
Last Price 129.15
1st Support Level 125.70
2nd Support Level 124.41
3rd Support Level 123.46

See More

52-Week High 133.10
Last Price 129.15
Fibonacci 61.8% 120.13
Fibonacci 50% 116.12
Fibonacci 38.2% 112.11
52-Week Low 99.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar